Response to lorlatinib on a patient with ALK ‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis
| Autor: | Takashi Kobayashi, Takuro Noguchi, Shintaro Kanda, Nodoka Sekiguchi, Tomonobu Koizumi, Toshirou Fukushima |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
non‐small cell lung cancer
0301 basic medicine Pulmonary and Respiratory Medicine Alectinib medicine.drug_class Case Report Case Reports Metastasis gynecological metastasis 03 medical and health sciences 0302 clinical medicine lorlatinib hemic and lymphatic diseases medicine Anaplastic lymphoma kinase Lung cancer RC254-282 Ceritinib Crizotinib business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens General Medicine medicine.disease Lorlatinib ALK inhibitor 030104 developmental biology ALK Oncology 030220 oncology & carcinogenesis Cancer research 1151Tins business medicine.drug |
| Zdroj: | Thoracic Cancer Thoracic Cancer, Vol 12, Iss 16, Pp 2275-2278 (2021) |
| ISSN: | 1759-7714 1759-7706 |
| Popis: | We describe a case of an anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer with development of uterine metastasis after crizotinib and alectinib treatment. Gene analysis from the tissue of uterine metastasis revealed the presence of 1151Tins, which was considered to be a crizotinib and alectinib resistance mutation. Subsequent therapy with the third‐generation ALK inhibitor lorlatinib, but not ceritinib, showed antitumor activity for 1 year. The uterus is an uncommon site for metastasis from lung cancer, and our case indicated that serial gene analysis could provide new information about ALK inhibitor resistance. A patient with ALK‐rearranged advanced non‐small cell lung cancer presented acquired resistance to alectinib and uterine metastasis. Gene analysis using the tissue from the uterine metastasis revealed the presence of 1151Tins. Lorlatinib showed antitumor activity on this disease for one year. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|